What Regeneron's Quarter ended Sep 30, 2026 10-Q says: 2 signals
Regeneron filed its latest 10-Q with the SEC on Oct 30, 2026. It discusses compliance burden and major contract win.
Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn
Get Regeneron's live signals in Claude or ChatGPT, or by API
What changed at Regeneron this week? Use Autobound signals for regeneron.com.- Filed
- Oct 30, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 9
Source: Autobound Signal API · 93 signals tracked for Regeneron · updated
10-Q · latest 8
What Regeneron's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 2 signals
Regeneron Enters Landmark April 2026 Agreements with U.S. Government Covering Pricing and Tariffs
Regeneron announced agreements with the U.S.
In April 2026, Regeneron agreed to supply wholly owned U.S.
gene therapy
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 2 signals
In April 2026, Regeneron reached agreements with the U.S.
Agreements Reached with U.S. Government Covering Drug Pricing and Exemption from Section 232 Tariffs
In April 2026, Regeneron announced agreements with the U.S.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 5 signals
In April 2026, Regeneron reached agreements with the U.S.
Regeneron entered into agreements with the U.S.
TrumpRx.gov
FDA Delays EYLEA HD Syringe Review Across Catalent and Second Contract Filling Manufacturer
The FDA did not act by the April 2026 PDUFA date for a second contract manufacturer, following a site re-inspection at Catalent Indiana for EYLEA HD pre-filled syringes.
pre-filled syringeCatalent
FDA approved gene therapy Otarmeni and expanded Dupixent indications in Q1 2026
Regeneron secured FDA approval for Otarmeni (AAV-based gene therapy for OTOF-related hearing loss) and expanded approvals for Dupixent in AFRS and pediatric CSU.
AAV-based gene therapy
Showing 8 of 9 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Regeneron earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Expanded Sanofi alliance adds four next-gen antibodies with $1B upfrontRegeneron expanded its long-standing collaboration with Sanofi to advance four next-generation long-acting antibodies and bispecifics targeting type 2 inflammation pathways. Regeneron receives a $1 billion upfront payment in Q4 2026, with development costs and global profits split 50/50. This creates major opportunities for vendors supporting large-scale co-development and clinical trial... | |
| Total revenue up 36% with EPS growth of 70%Regeneron delivered its third consecutive quarter of double-digit top and bottom-line growth, with total revenue rising 36% year-over-year. Non-GAAP diluted net income per share grew 70% to $20.07 on net income of $2.2 billion, driven by strength in core commercial franchises. | |
| Differentiating NASH CIDEB siRNA mechanism against Madrigal and GLP-1sRegeneron highlighted that its CIDEB siRNA program directly targets a genetic driver of NASH, achieving 70% average liver fat reduction in 12 weeks. Management contrasted this direct mechanism against indirect metabolic therapies like Madrigal's agent and GLP-1 agonists such as semaglutide. Differentiated efficacy without requiring body weight reduction is positioned as a primary competitive... | |
| Advance multiple registrational trials driving mid-teens 2027 R&D growthRegeneron plans to advance nearly 15 Phase III trials across multiple therapeutic areas in 2027, expecting R&D expense to grow by a mid-teens percentage over 2026. The clinical acceleration spans myeloma, anticoagulation, obesity, POTS, and NASH. This sharp rise in clinical development spend creates opportunities for contract research organizations, diagnostic providers, and clinical trial... | |
| BARDA contract to supply Inmazeb doses through 2031Regeneron secured a new agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply additional treatment doses of Inmazeb to the U.S. government from late 2027 through 2031. Deliveries under the new contract will begin in late 2027, resulting in zero expected revenue from Inmazeb in Q4 2026. This multi-year federal commitment reinforces production requirements... | |
| In-licensed olatorepatide from Hansoh advancing into global phase 3Regeneron is advancing global development of olatorepatide, a dual GLP-1/GIP receptor agonist in-licensed from partner Hansoh. The company plans to initiate registrational trials combining the asset with Praluent to treat obesity with dyslipidemia. This supplier and licensing partner arrangement drives specialized formulation and manufacturing procurement for combination regimens. |
Signal API · MCP
Track Regeneron with the Signal API
One POST /v1/companies/enrich call with regeneron.com returns Regeneron 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Regeneron 10-Q
When did Regeneron file its latest 10-Q?
What did Regeneron disclose in its latest 10-Q?
What did Regeneron say on its recent earnings calls?
Where can I read Regeneron's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .